| Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis GR Lichtenstein, A Shahabi, SA Seabury, DN Lakdawalla, OD Espinosa, ... Clinical Gastroenterology and Hepatology 18 (4), 889-897. e10, 2020 | 81 | 2020 |
| Long-term health and economic value of improved mobility among older adults in the United States M Kabiri, M Brauer, J Shafrin, J Sullivan, TM Gill, DP Goldman Value in Health 21 (7), 792-798, 2018 | 29 | 2018 |
| An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does … J Shafrin, M Skornicki, M Brauer, J Villeneuve, M Lees, N Hertel, ... Health Policy 122 (6), 607-613, 2018 | 25 | 2018 |
| The potential impact of CAR T-cell treatment delays on society JT Snider, M Brauer, R Kee, K Batt, P Karaca-Mandic, J Zhang, ... Am J Manag Care 25 (8), 379-386, 2019 | 15 | 2019 |
| Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness J Shafrin, K Bognar, K Everson, M Brauer, DN Lakdawalla, FM Forma ClinicoEconomics and outcomes research, 573-585, 2018 | 14 | 2018 |
| CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments JR Baumgardner, MS Brauer, J Zhang, Y Hao, Z Liu, DN Lakdawalla Journal of Comparative Effectiveness Research 9 (5), 327-340, 2020 | 11 | 2020 |
| Increased lifetime risk of intestinal complications and extraintestinal manifestations in Crohn’s disease and ulcerative colitis GR Lichtenstein, A Shahabi, SA Seabury, DN Lakdawalla, OD Espinosa, ... Gastroenterology & Hepatology 18 (1), 32, 2022 | 10 | 2022 |
| Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis E van Eijndhoven, M Brauer, R Kee, J MacEwan, L Mucha, SL Wong, ... Journal of Medical Economics 23 (5), 474-483, 2020 | 10 | 2020 |
| The economic value of CTL019 therapy for pediatric patients with relapsed and refractory acute lymphoblastic leukemia in the United Kingdom J Snider, M Brauer, Y Hao, P Karaca-Mandic, MG Tebeka, J Zhang, K Batt Blood 130, 1330, 2017 | 7 | 2017 |
| Expanding cost-effectiveness analysis to all of health care: comparisons between CEAs on pharmaceuticals and medical/surgical procedures J Baumgardner, M Brauer, M Skornicki, P Neumann Los Angeles, 2018 | 5 | 2018 |
| Complications of Crohn's Disease and Ulcerative Colitis: Understanding the Lifetime Risks: 716 GR Lichtenstein, A Shahabi, SA Seabury, D Lakdawalla, OD Espinosa, ... Official journal of the American College of Gastroenterology| ACG 112, S395-S396, 2017 | 5 | 2017 |
| The Economic Burden of Crohn's Disease and Ulcerative Colitis in the United States: A Lifetime Healthcare Cost Analysis: 2017 Presidential Poster Award: 715 GR Lichtenstein, A Shahabi, SA Seabury, D Lakdawalla, OD Espinosa, ... Official journal of the American College of Gastroenterology| ACG 112, S395-S396, 2017 | 3 | 2017 |
| The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are … JT Snider, M Brauer, K Batt, P Karaca-Mandic, J Zhang, DP Goldman Journal of Clinical Oncology 36 (15_suppl), 10529-10529, 2018 | 2 | 2018 |
| P014 AVERAGE ANNUAL HEALTHCARE COSTS FOR PEDIATRIC AND ADULT PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS RN Baldassano, A Shahabi, SA Seabury, D Lakdawalla, O Diaz, S Green, ... Inflammatory Bowel Diseases 24 (suppl_1), S6-S6, 2018 | 2 | 2018 |
| Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure J Shafrin, ER Aliyev, M Brauer, S Park, X Shen Journal of Medical Economics 23 (12), 1450-1460, 2020 | 1 | 2020 |
| Adoption of Sacubitril/Valsartan to Treat Acute Decompensated Heart Failure Improves Health System Finances Under Value-based Alternative Payment Models J Shafrin, ER Aliyev, M Brauer, S Park, X Shen Circulation 142 (Suppl_3), A14302-A14302, 2020 | 1 | 2020 |
| CAR-T therapy displays favorable gains in health outcomes and competitive cost-effectiveness when compared with past innovative cancer treatments J Baumgardner, K Everson, M Brauer, J Zhang, Y Hao, J Liu, ... Blood 132, 322, 2018 | 1 | 2018 |
| The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States K Bognar, J Shafrin, M Brauer, L Zhao, R Hockett, M O’Neil, A Jena Journal of Medical Economics 21 (11), 1057-1066, 2018 | | 2018 |
| Does knowledge of patient non-compliance change prescribing behavior in the real world? a claims-based analysis of patients with serious mental illness K Bognar, K Everson, M Brauer, FM Forma | | 2018 |
| Do multiple sclerosis cost-effectiveness studies follow best practice guidelines? A review of 5 case studies (P3. 399) J Shafrin, D Kantor, M Brauer, J Ko, V Herrera, D Goldman Neurology 88 (16 Supplement), 2017 | | 2017 |
